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Abstract
Background: Allograft tolerance of ACI (RT1
a) recipients to WF (RT1
u) hearts can be induced by allochimeric class I MHC
molecules containing donor-type (RT1A
u) immunogenic epitopes displayed on recipient-type (RT1A
a) sequences. Here, we
sought the mechanisms by which allochimeric sequences may affect responding T cells through T cell receptor (TCA)
repertoire restriction.
Methodology/Principal Findings: The soluble [a1h
u]-RT1.A
a allochimeric molecule was delivered into ACI recipients of WF
hearts in the presence of sub-therapeutic dose of cyclosporine (CsA). The TCR Vb spectrotyping of the splenocytes and
cardiac allografts showed that the Vb gene families were differentially expressed within the TCR repertoire in allochimeric-
or high-dose CsA-treated tolerant recipients at day +5 and +7 of post-transplantation. However, at day 30 of post-
transplantation the allochimeric molecule-treated rats showed the restriction of TCR repertoire with altered dominant size
peaks representing preferential clonal expansion of Vb7, Vb11, Vb13, Vb 14, and Vb15 genes. Moreover, we found a positive
correlation between the alteration of Vb profile, restriction of TCR repertoire, and the establishment of allograft tolerance.
Conclusions: Our findings indicate that presentation of allochimeric MHC class I sequences that partially mimic donor and
recipient epitopes may induce unique tolerant state by selecting alloresponsive Vb genes.
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Introduction
The possible mechanisms underlying the development of
transplantation tolerance include clonal deletion of alloreactive
cells, clonal anergy, cell-mediated suppression, and ‘‘infectious’’
tolerance [1]. Studies on the mechanisms responsible for the
establishment of transplantation tolerance point to the immune
regulation as the major determinant. It was shown previously that
the CD4+ T lymphocytes from tolerate hosts inhibit rejection of
donor-specific allografts after adoptive transfer into test rat
recipients [2] and the examination of tolerant cardiac allografts
in both early and late post-transplantation stages indicated that in
contrast to the rejecting grafts they were extensively infiltrated by
the T cells [3,4]. Following allotransplantation, the T cells can
recognize graft MHC antigens in two different ways: via ‘‘direct’’
recognition of antigens on donor cells and via ‘‘indirect’’
recognition of processed donor antigens presented on recipients
APCs in the form of peptides combined with MHC molecules [5].
Numerous studies on rodents and humans demonstrate that the
indirect recognition of MHC plays a major role in both acute and
chronic allograft rejection [6–8].
In response to alloreaction, T cells react to allogeneic MHC
molecules by displaying a dominant determinant on donor MHC
antigens and are restricted by self-MHC elements [9–11]. It was
shown previously that the alteration of critical amino acid residues
in such immunodominant determinants inhibited T cell prolifer-
ative responses, induced T cell anergy and altered host immune
responses toward native antigens [12–15]. Furthermore, analysis
of T cell responses to nominal protein or transplantation antigens
has shown that constraints in antigen processing and presentation
usually limit the T cell responses to one or two dominant
determinants [3], and that, in humans, T cells responding to
dominant allopeptides had limited TCR-Vb gene usage [10,11].
Thus, indirect allorecognition by T cell possibly regulates specific
immunointervention [16–19] through manipulation of such
dominant immunogenic epitopes.
Previously we have mapped an immunogenic determinant for
rat class I RT1
u, RT1
l and RT1
a alloantigens to amino acid
residues 58–80 on a1-helical polymorphic region [20,21]. MHC
alloantigens are therefore similar to multideterminant protein
antigens that bear localized immunodominant amino acid
sequences that trigger immune responses toward the whole protein
molecule [22–25]. Therefore, monitoring the profile of alteration
of TCR repertoire will provide a proof of indirect recognition of
MHC molecules through TCR restriction.
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determining region 3 (CDR3)
3 of TCR Vb have been observed
in vitro and in vivo during allorecognition [5]. Indirect [a1h
u]-
RT1.A
a allochimeric recognition may induce functionally unique
regulatory T cells with distinctive TCR allospecificities. To test this
hypothesis, we have performed a comprehensive analysis of TCR
Vb gene usage in parallel with CDR3 spectrotyping of T cells. The
CDR3 length distribution (CDR3-LD) measurement of the
different Vb genes demonstrated the antigenic diversity recognized
by a T cell population. Our experiments provide direct evidence of
the ability of indirectly presented allochimeric sequences to select
the TCR repertoire and thus provide a powerful tool for
manipulating the immune response through the sequences of the
indirectly presented antigen. The characteristics of the TCR Vb
expression pattern may potentially be used as a novel marker to
identify operational regulatory T cells in the recipient of organ
allograft.
Results
Induction of Tolerance by [a1h
u]-RT1.A
a to WF (RT1.A
u)
Allograft in ACI (RT1.A
a) Recipient
We had constructed an immunogenic [a1h
u]-RT1.A
a molecule
by altering hypervariable a1-helical region (a.a. 51–90) of ACI
(RT1.A
a) to WF (RT1.A
u) sequences [20,26]. The resulted [a1h
u]-
RT1.A
a molecule bears both RT1.A
u and RT1.A
a a1-helical
epitopes. We have previously demonstrated [20,26] that peri-
transplant portal venous (p.v.) administration of [a1h
u]-RT1.A
a
allochimeric molecules induced tolerance to WF (RT1
u) heart
allografts in ACI (RT1
a) recipients, when administered in
conjunction with sub-therapeutic dose of CsA [31]. This indicates
that peri-transplant administration of syngeneic class I sequences
flanking allogeneic a1-helical immunogenic epitopes, in combina-
tion with a brief sub-therapeutic dose of CsA, is able to induce
donor-specific transplantation tolerance.
TCR Responses in Long-Term Tolerant Allochimeric
Conditioned Recipients
CDR3 spectrotyping shows three to seven visible bands of
different size for each Vb gene product, which intensities follow
Gaussian distribution. Twenty two samples of TCR Vb profile
plots (derived from DNA Analyzer and Genotyper 3.7 software)
from CsA-treated long-term tolerant ACI hosts bearing allochi-
meric [a1h
u]-RT1.A
a class I allografts are shown in Fig. 1A. The
TCR Vb profile plots from the allografts of CsA-induced long-
term tolerant recipients were similar to the profile plots from the
recipients’ spleen cells (Fig. 1B). In several profile plots (e.g., Vb3,
8.1, 13, 14, and 19) we observed minor alterations in pick
distribution patterns between allograft and spleen cells. Because
these alterations were inconsistent between experiments we believe
that they represent data output ‘‘noise’’ inherent to the applied
method of analysis. In summary, it seems that a broad
immunosuppressive agent such as CsA is unable to induce a
clonal restriction of TCR.
In all (n=12) examined long-term (120 days) tolerant hosts
induced by allochimeric protein [a1h
u]-RT1.A
a, all twenty two
TCR Vb genes exhibited constant restriction with altered
dominant size peaks in Vb7, 11, 13, 14, 15 (Fig. 2A). We also
observed the alteration in the regular Gaussian distribution of 7–
11 peaks in the following Vbs: 1, 2, 3, 4, 5, 8.1, 10, 12, and 16.
To confirm that restrictions of TCR repertoire (i.e. the
oligoclonal expansion of T cells) were unique to the graft site
rather than being a general feature of T cells of tolerant recipients,
we also performed spectrotyping of the host splenocytes. Figure 2B
shows that, indeed, these unique dominant peaks were detected
exclusively in heart allografts, and were absent in splenocytes from
the same tolerant host. Thus, all restrictions of TCR repertoire
observed in our studies were allograft-specific.
Frequency of Oligoclonality of T Cells in Tolerated Grafts
The algorithm for calculating the percentage of alterations of
expression profile gene and percentage of expression frequency for
each Vb gene were performed as described in the legend to
Fig. 3A. We found that the expression frequencies of individual Vb
genes varied in a series of twelve grafts from allochimeric protein-
treated rats (Fig. 3A). On the other hand, the Pearson correlation
analysis indicated that there was no significant difference between
the expression frequency of various Vbs in CsA-treated and
allochimeric-protein treated rats (Correlation coeffi-
cient=20.00938; P=0.9669).
Although all twenty two Vb gene products were readily
detectable in each individual graft from both CsA and allochimeric
protein-treated tolerant rats, the overall Vb usage was restricted
only in allochimeric protein-treated rats. As summarized in
Figure 3B, the restriction frequencies of individual Vb genes
varied in grafts from allochimeric protein-treated tolerant rats: the
Vb4, 8.3, 10, 12, 16 were slightly restricted in most of the
transplants and Vb7, 11, 13, 14, 15 displayed dominant restricted
bands, while Vb1, 3.3, 8.2, 9, 19 were expressed much less
frequently (Fig. 3A and 3B). Interestingly, there was no correlation
between the frequency of expression of particular Vb genes and
their restriction level (Fig. 3A). This indicates that only selective
Vb gene families underwent significant clonal expansion and that
the restriction of Vb genes was not related to their expression level.
Interestingly, CDR3 spectrotyping of Vb gene products showed
remarkable differences between allochimeric-protein- and CsA-
treated rats. Two-sample t-test analysis of the differences of the
detection frequency of Vb restricted in total TCR repertoire
between CsA and allochimeric protein-induced tolerant rats
showed 6% restriction frequency in CsA-treated tolerant allograft
versus 36% in allochimeric protein -treated allograft (Fig. 3B). This
difference was statistically significant (t=6.2; P,0.0001).
Dynamic Alteration of T Cell Receptor Repertoire in CsA
and Allochimeric Conditioned Long-Term Tolerant Hosts
To analyze the restriction pattern of TCR repertoire, the RNA
was harvested at the different post-transplantation time points, at
day 5, 7, 30, and .100 from CsA- and allochimeric protein-
treated tolerant rats and then subjected to CDR3 spectrotyping
(Fig. 4). The restriction of TCR repertoire in allochimeric protein
conditioned tolerant recipients did not occur before 30 days of
post-transplantation, and dominant CDR3 bands in Vb7, 11, 13,
14, 15 gene products were found more frequently at 100 days post-
transplantation (Fig. 4B). In contrast, nearly all Vb gene products
were unrestricted throughout the whole post-transplantation
period in CsA induced long-term tolerant hosts (Fig. 4A).
Discussion
Our previous data suggested that tolerance might be induced by
functional presentation of donor immunogenic epitopes via self-
sequences [20,26]. Since processing of allochimeric molecules may
alter the repertoire of alloreactive T cells, we applied CDR3
spectrotyping of TCR repertoire to analyze the clonal expansion
of T cells in allografted hearts of tolerant recipients. Spectrotyping
has been successfully used to analyze T cell responses to some well-
characterized peptide antigens in vivo [31–33]. In current studies,
we first determined whether there is any preferential accumulation
T Cell Receptor
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spectrotyping can detect T cell clones against a background of
polyclonal cells at a frequency of at least 1 in 1000 [34–36], we
then used this novel technique to identify clonally expanded T cells
by comparing CDR3 patterns in CsA and allochimeric protein-
treated rats. We found that most of Vb genes were expressed at the
similar levels in long-term tolerant rats induced by CsA and
allochimeric treatment and clonal expansion occurred only in a
limited number of Vb genes and was consistently observed in Vb7,
11, 13, 14, 15. In contrast, no restricted clonal expansion was
found in either spleencytes or CsA treated tolerant. The restricted
clonal expansion observed in our study may indicate the presence
of suppressed alloreactive T cells or preferential activation of
putative regulatory T cells. Based on our previous findings, we
argue that these cells are the regulatory cells [30,38,40].
Functional relevance of the oligoclonal T cell expansion can be
addressed by using Vb-specific mAb to selectively target specific
Vb gene products [41]. However, at present, this method is limited
because only few anti-Vb antibodies are available. An alternative
method to test the functional relevance of T cell oligoclonality is
the newly developed technique of TCR-specific DNA vaccination
that inactivates targeted T cell clone(s) [42]. Our current study is
the first to document a unique pattern of CDR3 spectrotyping in
the tolerance pathway induced by allochimeric protein. Thus, our
experimental design will allow us to further address the
mechanism through which the indirectly presented allochimeric
Figure 1. RT-PCR-assisted detection of expression profile of 22 known rat TCR Vb genes in CsA-induced long-term tolerant ACI
recipients bearing WF heart allografts (survival day.100). (A) TCR Vb gene expression profile plots from heart allografts. A fluorochrome-
labeled primer derived from b chain constant region was used for run-off reactions for each Vb-specific RT-PCR product, and the fluorescent run-off
products were analyzed in 3700 DNA Analyzer, as described in Materials and Methods. Panel numbers correspond to the numbers of individual Vb
genes. (B) TCR Vb expression profile plots from splenocytes.
doi:10.1371/journal.pone.0006076.g001
T Cell Receptor
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many important implications for tolerance induction and inhibi-
tion of chronic rejection. Identification of the specific T cells
involved in these processes may also provide an important tool to
design intervening reagents in clinical treatment.
The mechanism of the recognition of allochimeric MHC
molecules and T cells remains unclear. It was hypothesized that
T cells selected by self-MHC molecules in the thymus could
proliferate and mutate their receptors to allow them preferentially
to recognize ‘‘altered-self’’ MHC molecules [39,43,44]. A
restricted oligoclonal rather than a single clonal expansion of the
Vb TCR repertoire observed in our study indicates a pattern of
hierarchical immunodominance or a cross-reactive response to
cryptic self epitopes when regulatory cells are generated in
response to self-peptide antigens. This issue can be addressed by
dissecting the TCR repertoire using a second allochimeric
molecule which shares similar self-RT1.A
a sequences to allochi-
meric molecule [a1h
u]-RT1.A
a, but differs in the substituted
immunogenic RT1.A
u epitope. Comparison of the TCR reper-
toire in tolerant hosts following allochimeric treatment with either
molecule may identify shared CDR3 expansions indicative of
regulatory cell clonality induced by shared self-sequences. Our
CDR3 spectrotyping analysis of the TCR Vb genes in allochi-
meric tolerant rats demonstrated predominant and consistent
clonal expansion of the Vb7, 11, 13, 14 and 15 genes. However,
our data showed that the alteration Vbs in allochimeric protein-
treated tolerant rats would not occur until after 30 days post-
transplantation. This intriguing finding may indicate the estab-
Figure 2. RT-PCR-assisted detection of expression profile of 22 known rat TCR Vb genes in allochimeric protein [a1h
u]-RT1.A
a class I
molecule -induced long-term tolerant ACI recipients bearing WF heart allografts (survival day.100). (A) TCR Vb gene expression profile
plots from heart allografts. (B) TCR Vb gene expression profile plots from splenocytes.
doi:10.1371/journal.pone.0006076.g002
T Cell Receptor
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may be explained by a sequential activation of T cells over time
with subsequent spreading of the response [37].
Though it has beendemonstrated that maintenance of regulatory
cells is dependant on the continuous supply of antigenic stimulation
by the allograft [45], it has not been possible to differentiate their
potential functional diversity in vivo because in most studies,
tolerance induction and allograft survival were the endpoints of
the analysis [46]. In our studies, we utilized two primary therapies-
CsA and allochimeric molecules to achieve distinctive tolerant
states, which in turn elicited different responses of TCR repertoire.
Such unique TCR restriction model will allow us to examine the
functional characteristics and allospecific specificities of regulatory
cells based on the inducing therapeutic agent.
Materials and Methods
Animals
Adult male inbred Wistar Furth (WF; RT1
u) and ACI (RT1
a)
rats (200–250 g) were purchased from Harlan Sprague Dawely
(Indianapolis, IN) and housed in wire-bottomed cages with
controlled light/dark cycle. Rats were given free access to water
and standard rat chow and were cared for according to the
guidelines of the American Association of Laboratory Animal
Care. All experiments were performed according to the NIH
standards as set forth in the ‘‘Guide for the Care and Use of
Laboratory Animals’’ (DHHS publication No. (NIH) 85–23
Revised 1985). The Institution also accepts as mandatory the
PHS ‘‘Policy on Humane Care and Use of Laboratory Animals’’
Figure 3. The frequency of oligoclonality and of Vbs expression in TCR repertoire in long-term (.100 days) tolerant CsA and
allochimeric protein-treated, ACI recipients of WF cardiac allografts. The frequency of expression and oligoclonality for each Vb gene was
calculated as a percentage of the total frequency of detection of each Vb in all (positive and negative) PCR amplification experiments. (b) There is
significant difference between the frequency of Vbs restriction in the TCR repertoire between CsA- (blue) and allochimeric protein-treated (purple)
rats. (a) There was no correlation between expression frequency (purple) and oligoclonality frequency (blue) in allochimeric protein-treated rats.
Vb7, 11, 13, 14, 15 gene products show 1-3 dominant peaks, indicating TCR restriction in the T cell repertoire in allochimeric protein-induced tolerant
rats. (A)
doi:10.1371/journal.pone.0006076.g003
T Cell Receptor
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Animals Used in Testing, Research and Training.
Site-Directed Mutagenesis and Production of Mutant
Class I MHC Molecules
Mutagenesis primers (purified by PAGE) were obtained from
Invitrogen (Carlsbad, CA). The ‘‘QuickChange Multi Site-Directed
Mutagenesis Kit’’ (Stratagene, San Diego, CA) was used to mutate
ACI-RT1
a cDNA as described previously [20,26] and resulting
plasmids were sequenced to confirm the presence of the mutations.
Production of Allochimeric Protein Containing Mutant
Class I MHC Molecules and Allograft Model
The allochimeric proteins containing [a1h
u]-RT1.A
a sequence
were expressed in transfected Buffalo hepatoma cells as described
previously [26]. For tolerance induction, allochimeric proteins
were administered through the portal vein (1 mg/rat) into ACI
recipients of WF hearts at the time of transplantation followed by a
3-day course of oral cyclosporine delivered by gavage feed (CsA,
10 mg/kg/day; day 0–2). Controls included transplantation of
allogeneic hearts in the presence or absence of the same dose of
CsA. Heterotopic cardiac transplants were placed intra-abdomi-
nally [27].
TCR Vb RT-PCR
RNA was extracted from splenocytes and allografted cardiac
hearts at post-transplantation day 5, 7, 10, 30, 84, 120 and .120
using the Qiagen RNeasy Mini Kit (QIAGEN, Valencia, CA). In
order to remove DNA contamination the RNA samples were
digested with DNase I (RNase-free DNase Set, Cat. 79254,
QIAGEN) and 25 mg of RNA was reverse transcribed into cDNA
Figure 4. The dynamic alteration of T cell receptor repertoire in CsA (A) and allochimeric conditioned (B) long-term tolerant hosts.
RNAs from heart allografts were harvested at different time points after transplantation followed by TCR detection. There were .7 samples for each
time-point.(B) (A) There was no TCR restriction in the hearts of CsA treated tolerant recipients throughout the whole period of long-term tolerance
(.day 120). (B) There was no TCR restriction in the hearts of allochimeric protein-treated tolerant recipients until 30 days post-transplantation.
However, the Vb7, 11, 13, 14 and15 were highly restricted and occurred as the dominant peaks 84 days after transplantation. This restriction was
maintained throughout the whole period of long-term tolerance (.day 120),
doi:10.1371/journal.pone.0006076.g004
T Cell Receptor
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SuperScript First-Strand Synthesis System from RT-PCR kit
(Invitrogen, Carlsbad, CA). Rat Vb-specific primers were chosen
according to Shirwan et al. [28] with minor modifications [29]. A
total of 2 ml of cDNA was amplified using a fixed down-stream
primer (Cb1) derived from TCR b chain constant region, and one
of the 22 different Vb-specific upstream primer. Amplification
reactions were conducted in a GeneAmp PCR System 9700. The
reactions started with a 10 min denaturation step at 94uC,
followed by 35 cycles of 30 sec at 94uC, 30 sec at 55uC, and
1 min at 72uC, and ended with an elongation step of 7 min at
72uC.
Spectrotyping of TCR Vb CDR3
A 6-FAM-labeled internal primer within the Vb PCR products
(Cb2 derived from b chain constant region) was synthesized by
Applied Biosystems (Foster, CA). 7.5 ml of each Vb-specific PCR
product was subjected to 15 cycles of run-off reactions in a final
volume of 10 ml, consisting of 0.25 rM of fluorochrome (FAM)-
labeled internal primer Cb2, 0.2 mM of each dNTP, 2 mM
MgCl2, and 0.2 U AmpliTaq Gold (Perkin Elmer, Foster City,
CA) in 16 PCR Gold buffer. Amplification was conducted in a
GeneAmp PCR System 9700 (Perkin Elmer), with cycle conditions
as follows: denaturation at 95uC for 10 min, 15 cycles of 30 sec at
95uC, 30 sec at 58uC, and 30 sec at 72uC, and elongation at 72uC
for 5 min. At the end of the reaction, 5 ml of each spectrotyping
reaction was mixed with 10 ml of GeneScan LIZ 500 Size
Standard (Applied Biosystems, Foster, CA) in 96-well plate. After the
denaturation at 94uC for 5 min followed by incubation on ice for
5 min, the 96-well plate was analyzed using 3700 DNA Analyzer
(Applied Biosystems, Foster, CA).
Processing of Gel Images
The initial images from DNA Analyzer system were converted
into profile plots and the Vb CDR3 region profiles were visualized
using ABI Prism Genotyper 3.7 software. The lanes of each Vb
gene product were selected for profile plot. The plots were then
copied to Microsoft Powerpoint files. Two-sample t-test was
applied to detect the differences of restriction frequencies of TCR
repertoires in CsA and allochimeric protein treated rat tolerant
models. Pearson correlation coefficient analysis was performed to
determine whether the expression frequency of TCR repertoire
correlated with its restriction frequency in allochimeric molecules-
induced tolerant recipients. A P value of ,0.05 was used to
indicate significance.
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